Abstract
Deregulation of cell signaling pathways controlling cell growth and cell survival is a common feature of all cancers. Although a core repertoire of oncogenic mechanisms is widely conserved between various malignancies, the constellation of pathway activities can vary even in patients with the same malignant disease. Modern molecularly targeted cancer drugs intervene in cell signaling compensating for pathway deregulation. Hence characterizing tumors with respect to pathway activation will become crucial for treatment decisions. Here we have used semi-supervised machine learning methodology to generate signatures of eight oncogene-inducible pathways, which are conserved across epithelial and lymphoid tissues. We combined them to patterns of pathway activity called PAPs for pathway activation patterns and searched for them in 220 morphologically, immunohistochemically and genetically well-characterized mature aggressive B-cell lymphomas including 134 cases with clinical data available. Besides Burkitt lymphoma, which was characterized by a unique pattern, the PAPs identified four distinct groups of mature aggressive B-cell lymphomas across independent gene expression studies with distinct biological characteristics, genetic aberrations and prognosis. We confirmed our findings through cross-platform analysis in an independent data set of 303 mature aggressive B-cell lymphomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353–357.
West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001; 98: 11462–11467.
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431–2442.
Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419–2430.
Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862.
Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879.
Edgar R, Domrachev M, Lash AE . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207–210.
Huber W, von Heydebreck A, Sültmann H, Poustka A, Vingron M . Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 (Suppl 1): 96–104.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249–264.
Kostka D, Spang R . Microarray based diagnosis profits from better documentation of gene expression signatures. PLoS Comput Biol 2008; 4: e22.
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM . A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996.
von Heydebreck A, Huber W, Poustka A, Vingron M . Identifying splits with clear separation: a new class discovery method for gene expression data. Bioinformatics 2001; 17 (Suppl 1): S107–S114.
Shipp MA . Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ‘high-risk’ disease? Blood 1994; 83: 1165–1173.
Kreuz M, Rosolowski M, Berger H, Schwaenen C, Wessendorf S, Loeffler M et al. Development and Implementation of an analysis tool for array-based comparative genomic hybridization. Methods Inf Med 2007; 46: 608–613.
Pollard KS, Dudoit S, van der Laan MJ . Multiple testing procedures: the multtest package and applications to genomics. In: Gentleman R, Carey VJ, Huber W, Irizarry R, Dudoit S (eds). Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer: New York, 2005. pp 249–271.
Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183–3190.
Fenton JA, Schuuring E, Barrans SL, Banham AH, Rollinson SJ, Morgan GJ et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2006; 45: 164–168.
Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A . T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19: 652–658.
Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19: 1299–1305.
Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065–1072.
Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS . Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933–2935.
Acknowledgements
This work was carried out within the framework of the research network ‘Molecular Mechanisms in Malignant Lymphoma’ (MMML), supported by the Deutsche Krebshilfe (70-3173-Tr3). In addition R Spang announces support by the Bavarian Genome Network BayGene and AHB is supported by the Leukaemia Research Fund.
Members of MMML project are: Pathology group: Wolfram Klapper, Monika Szcepanowski, Thomas Barth, Wolfram Bernd, Alfred Feller, Martin-Leo Hansmann, Peter Möller, German Ott, Hans-Konrad Müller-Hermelink, Andreas Rosenwald, Hans-Heinrich Wacker, Sergio Cogliatti, Michael Hummel, Harald Stein. Genetics group: Carsten Schwaenen, Swen Wessendorf, Heiko Trautmann, Jose-Ignacio Martin-Subero, Eugenia Haralambieva, Judith Dierlamm, German Ott, Andreas Rosenwald, Thomas Barth, Christiane Pott, Ralf Küppers, Reiner Siebert. Bioinformatics group: Maciej Rosolowski, Rainer Spang, Hilmar Berger, Stefan Bentink, Dirk Hasenclever, Markus Loeffler. Project coordination: Benjamin Stürzenhofecker, Hilmar Berger, Michael Hummel, Lorenz Trümper. Steering Committee: Reiner Siebert, Harald Stein, Markus Loeffler, Lorenz Trümper.
Author information
Authors and Affiliations
Consortia
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Bentink, S., Wessendorf, S., Schwaenen, C. et al. Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia 22, 1746–1754 (2008). https://doi.org/10.1038/leu.2008.166
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.166
Keywords
This article is cited by
-
A modular transcriptome map of mature B cell lymphomas
Genome Medicine (2019)
-
Comparative gene-expression profiling of the large cell variant of gastrointestinal marginal-zone B-cell lymphoma
Scientific Reports (2017)
-
Diagnostik maligner Lymphome
Der Onkologe (2015)
-
Grauzonenlymphome
Der Pathologe (2013)
-
Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas
Cell Communication and Signaling (2012)